<SEC-DOCUMENT>0001140361-22-019614.txt : 20220517
<SEC-HEADER>0001140361-22-019614.hdr.sgml : 20220517
<ACCEPTANCE-DATETIME>20220517163036
ACCESSION NUMBER:		0001140361-22-019614
CONFORMED SUBMISSION TYPE:	NT 10-Q
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220517
DATE AS OF CHANGE:		20220517
EFFECTIVENESS DATE:		20220517

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Brooklyn ImmunoTherapeutics, Inc.
		CENTRAL INDEX KEY:			0000748592
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				311103425
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		NT 10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11460
		FILM NUMBER:		22934971

	BUSINESS ADDRESS:	
		STREET 1:		140 58TH STREET, BUILDING A
		STREET 2:		SUITE 2100
		CITY:			BROOKLYN
		STATE:			NY
		ZIP:			11220
		BUSINESS PHONE:		(212) 582-1199

	MAIL ADDRESS:	
		STREET 1:		140 58TH STREET, BUILDING A
		STREET 2:		SUITE 2100
		CITY:			BROOKLYN
		STATE:			NY
		ZIP:			11220

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NTN BUZZTIME INC
		DATE OF NAME CHANGE:	20051230

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NTN COMMUNICATIONS INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ALROY INDUSTRIES INC
		DATE OF NAME CHANGE:	19850411
</SEC-HEADER>
<DOCUMENT>
<TYPE>NT 10-Q
<SEQUENCE>1
<FILENAME>brhc10037838_nt10q.htm
<DESCRIPTION>NT 10-Q
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using EDGARfilings PROfile 8.2.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div style="text-align: center; font-size: 14pt; font-weight: bold;">UNITED STATES</div>
      <div style="text-align: center; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
      <div style="text-align: center; font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>
      <div><br>
      </div>
      <div style="text-align: center; font-size: 18pt; font-weight: bold;">FORM 12b-25</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="z34cd8054da2042f4aa1fe0f253046833" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 73%; vertical-align: top; padding-bottom: 2px;" colspan="1">&#160;</td>
            <td style="width: 12%; vertical-align: top; padding-bottom: 2px;">SEC File Number:</td>
            <td style="width: 15%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>001-11460</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 73%; vertical-align: top; padding-bottom: 2px;" colspan="1">&#160;</td>
            <td style="width: 11%; vertical-align: top; padding-bottom: 2px;">CUSIP Number:</td>
            <td style="width: 16%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>114082100</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: center; font-weight: bold;">NOTIFICATION OF LATE FILING</div>
      <div style="text-indent: -63pt; margin-left: 63pt;"><font style="font-style: italic;"> <br>
        </font></div>
      <div style="text-indent: -63pt; margin-left: 63pt;"><font style="font-style: italic;">(Check One)</font>: &#160; &#160; &#160; &#9744;&#160; Form 10-K&#160;&#160; &#9744;&#160; Form 20-F&#160;&#160; &#9744;&#160; Form 11-K&#160;&#160; &#9746;&#160; Form 10-Q&#160;&#160; &#9744;&#160; Form 10-D&#160;&#160; &#9744;&#160; Form N-CEN &#9744;&#160; Form N-CSR </div>
      <div style="margin-left: 72pt;">For Period Ended: <u>March 31, 2022 &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;</u> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <br>
      </div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 36pt;">&#9744;&#160; Transition Report on Form 10-K</div>
      <div style="text-indent: 36pt; margin-left: 36pt;">&#9744;&#160; Transition Report on Form 20-F</div>
      <div style="text-indent: 36pt; margin-left: 36pt;">&#9744;&#160; Transition Report on Form 11-K</div>
      <div style="text-indent: 36pt; margin-left: 36pt;">&#9744;&#160; Transition Report on Form 10-Q</div>
      <div style="text-indent: 36pt; margin-left: 36pt;">For the Transition Period Ended: ________________________</div>
      <div><br>
      </div>
      <div style="text-align: center;">Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.</div>
      <div><br>
      </div>
      <div>If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:</div>
      <div><br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"><br>
      </div>
      <div style="font-weight: bold;">PART I -- REGISTRANT INFORMATION</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="zc70b95a693f64345b0178bc036a965f7" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 100%; vertical-align: top; border-bottom: 2px solid black;">
              <div>Brooklyn ImmunoTherapeutics, Inc.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top;" rowspan="1">
              <div>Full Name of Registrant</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z39e099a6736646a1919326999bf9decd" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 100%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top;">
              <div>Former Name if Applicable</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z43d4c697e5734452a15cca5e53ca9eaf" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 100%; vertical-align: top; border-bottom: 2px solid black;">
              <div>10355 Science Center Drive, Suite 150</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top;" rowspan="1">
              <div>Address of Principal Executive Office<font style="font-style: italic;"> (Street and Number)</font></div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="zd27caf1c76f9492a875b12704a37ae9e" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 100%; vertical-align: top; border-bottom: 2px solid black;">
              <div>San Diego, California 92121</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top;" rowspan="1">
              <div>City, State and Zip Code</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="font-weight: bold;">PART II -- RULES 12b-25(b) AND (c)</div>
      <div><br>
      </div>
      <div>If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="z4c578510990748c6a2ff9e58168b4dcb" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 4%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div>(a)</div>
            </td>
            <td style="width: 91%; vertical-align: top;">
              <div>The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: middle; border-right: 2px solid rgb(0, 0, 0);">&#9746;</td>
            <td style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div>(b)</div>
            </td>
            <td style="width: 91%; vertical-align: top;">
              <div>The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed&#160; on or before the fifteenth calendar day following the prescribed due date;
                or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div>(c)</div>
            </td>
            <td style="width: 91%; vertical-align: top;">
              <div>The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div>
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="font-weight: bold;">PART III-- NARRATIVE</div>
      <div><br>
      </div>
      <div>State below in reasonable detail why the Form 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR or the transition report portion thereof, could not be filed within the prescribed time period. (Attach extra sheets if needed.)</div>
      <div><br>
      </div>
      <div>Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the &#8220;<u>Company</u>&#8221;, &#8220;<u>we</u>&#8221;, &#8220;<u>us</u>&#8221; or &#8220;<u>our</u>&#8221;), is filing this Notification of Late Filing on Form 12b-25 with respect to its Quarterly Report on Form 10-Q for the three
        months ended March 31, 2022 (the &#8220;<u>Form 10-Q</u>&#8221;).</div>
      <div><br>
      </div>
      <div style="text-align: justify;">The Company could not file the Form 10-Q within the prescribed time period required for smaller reporting companies without unreasonable effort and expense because additional time is required by the Company&#8217;s
        management to complete its preparation of the financial statements and accompanying disclosures for the period ended March 31, 2022.</div>
      <div><br>
      </div>
      <div style="text-align: justify;">In particular, the Company is reviewing certain valuation methodologies used to value both the IRX-2 assets acquired by the Company and the related contingent consideration obligations assumed by the Company in its
        2018 acquisition of IRX Therapeutics, Inc. and any internal control implications.&#160; The Company is diligently working towards filing the Form 10-Q no later than the fifth calendar day following the prescribed due date.</div>
      <div><br>
      </div>
      <div style="font-weight: bold;">PART IV -- OTHER INFORMATION</div>
      <div><br>
      </div>
      <div>(1)&#160; Name and telephone number of person to contact in regard to this notification</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" align="center" id="zb3643a85298f4a46adedc92379d75ca1" style="border-collapse: collapse; width: 80%; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left;">

          <tr>
            <td style="width: 30%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center;">Sandra Gurrola</div>
            </td>
            <td style="width: 2%; vertical-align: top;">&#160;</td>
            <td style="width: 16%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center;">(619)</div>
            </td>
            <td style="width: 2%; vertical-align: top;">&#160;</td>
            <td style="width: 30%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center;">957-3015</div>
            </td>
          </tr>
          <tr>
            <td style="width: 30%; vertical-align: top;">
              <div style="text-align: center;">(Name)</div>
            </td>
            <td style="width: 2%; vertical-align: top;">&#160;</td>
            <td style="width: 16%; vertical-align: top;">
              <div style="text-align: center;">(Area Code)</div>
            </td>
            <td style="width: 2%; vertical-align: top;">&#160;</td>
            <td style="width: 30%; vertical-align: top;">
              <div style="text-align: center;">(Telephone Number)</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div>(2)&#160; Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter&#160; period that the registrant was
        required to file such report(s) been filed? If the answer is no, identify report(s). &#9746; Yes&#160; &#9744; No</div>
      <div> <br>
      </div>
      <div>
        <div>
          <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      </div>
      <div><br>
      </div>
      <div>(3)&#160; Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?</div>
      <div style="text-align: right;">&#9746; Yes&#160; &#9744;&#160; No</div>
      <div><br>
      </div>
      <div>If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z3bb1bc6d987e46589d666b7441d6b127" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 100%; vertical-align: top; border-bottom: 2px solid black;">
              <div style="font-weight: bold;">See Annex A</div>
            </td>
          </tr>

      </table>
      <div style="text-align: center;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" align="center" id="z028d75eb75214a5c858deef1bd113c4a" style="border-collapse: collapse; width: 70%; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left;">

          <tr>
            <td style="width: 70%; vertical-align: top; border-bottom: 2px solid black; font-size: 24pt;">
              <div style="text-align: center;">Brooklyn ImmunoTherapeutics, Inc.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 70%; vertical-align: top;">
              <div style="text-align: center;">(Name of Registrant as Specified in Charter)</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div>has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="z22ce738dd911410b9aca4a18fccb0a90" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 5%; vertical-align: top;">
              <div>Date: </div>
            </td>
            <td style="width: 25%; vertical-align: top; border-bottom: 2px solid black;">
              <div>May 17, 2022</div>
            </td>
            <td style="width: 37%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">
              <div>By</div>
            </td>
            <td style="width: 30%; vertical-align: top; border-bottom: 2px solid black;">
              <div>/s/ Howard Federoff</div>
            </td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 25%; vertical-align: top;">&#160;</td>
            <td style="width: 37%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">&#160;</td>
            <td style="width: 30%; vertical-align: top;">
              <div>Howard Federoff</div>
            </td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 25%; vertical-align: top;">&#160;</td>
            <td style="width: 37%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">&#160;</td>
            <td style="width: 30%; vertical-align: top;">
              <div>Chief Executive Officer and President</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center;">Annex A</div>
      <div><br>
      </div>
      <div>As previously reported, on August 12, 2020, the Company (then known as &#8220;<u>NTN Buzztime, Inc.</u>&#8221;), Brooklyn LLC and BIT Merger Sub, Inc., a wholly owned subsidiary of the Company (&#8220;<u>Merger Sub</u>&#8221;), entered into an agreement and plan of
        merger and reorganization (the &#8220;<u>Merger Agreement</u>&#8221;) pursuant to which, among other matters, Merger Sub merged with and into Brooklyn LLC, with Brooklyn LLC continuing as a wholly owned subsidiary of the Company and as the surviving company of
        the merger (the &#8220;<u>Merger</u>&#8221;). The Merger closed on March 25, 2021. After the Merger, the Company changed its name from &#8220;NTN Buzztime, Inc.&#8221; to &#8220;Brooklyn ImmunoTherapeutics, Inc.&#8221; The Merger was accounted for as a reverse acquisition, in which
        Brooklyn LLC was deemed the acquiring company for accounting purposes.</div>
      <div><br>
      </div>
      <div>In accordance with the Merger Agreement, on March 25, 2021, the Company amended its restated certificate of incorporation in order to effect:</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z52ad51d37bcb4bfea1122f5cb891776b" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>prior to the Merger, a reverse stock split of its common stock, par value $0.005 per share, at a ratio of one-for-two; and</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zc311d5bb4763467c82b7769c4fea8cc1" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>following the Merger, a change in its corporate name from &#8220;NTN Buzztime, Inc.&#8221; to &#8220;Brooklyn ImmunoTherapeutics, Inc.&#8221;</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div>On March 26, 2021, we sold the rights, title and interest in and to the assets relating to the business operated under the name &#8220;NTN Buzztime, Inc.&#8221; prior to the Merger to eGames.com Holdings LLC, or eGames.com, in exchange for eGames.com&#8217;s
        payment of a purchase price of $2.0 million and assumption of specified liabilities relating to such pre-Merger business.</div>
      <div><br>
      </div>
      <div>The Merger has been accounted for as a reverse acquisition in accordance with U.S. generally accepted accounting principles, or GAAP. Under this method of accounting, Brooklyn LLC was deemed the &#8220;acquiring&#8221; company and Brooklyn
        ImmunoTherapeutics, Inc. (then known as NTN Buzztime, Inc.) was treated as the &#8220;acquired&#8221; company for financial reporting purposes. Operations prior to the Merger are those of Brooklyn LLC, and the historical financial statements of Brooklyn LLC
        became the historical financial statements of the Company with respect to periods prior to the completion of the Merger.</div>
      <div><br>
      </div>
      <div>Upon filing of the Form 10-Q, the Company will report its consolidated financial results for the three-months ended March 31, 2022 with respect to the business of Brooklyn ImmunoTherapeutics, Inc.</div>
      <div><br>
      </div>
      <div>For the three months ended March 31, 2022, the Company expects to report research and development expenses of $1.8 million as compared to $1.5 million for the three months ended March 31, 2021.</div>
      <div><br>
      </div>
      <div>For the three months ended March 31, 2022, the Company expects to report general and administrative expenses of $4.5 million as compared to $1.6 million for the three months ended March 31, 2021, primarily related to non-cash stock-based
        compensation expense from increased equity awards, increased headcount, and increased premiums for public company insurance policies.</div>
      <div><br>
      </div>
      <div>The Company expects to report that, at March 31, 2022, the Company had cash and cash equivalents of approximately $23.5 million.</div>
      <div><br>
      </div>
      <div><br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
